A Randomized, Single-dose, Crossover, Two-period, Pilot Comparative Bioavailability Study of Alendronate 70 mg effervescent vs. Fosamax 70 mg tablets in Healthy Male and Female Subjects.

2024-513615-26-00 Protocol 956/23 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 12 Sep 2024 · End 2 Oct 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 956/23

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 24
Countries 1
Sites 1

not applicable (submitted trial is a comparative bioavailability study)

Key facts

Sponsor
Oractive Swiss AG
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
12 Sep 2024 → 2 Oct 2024
Decision date (initial)
2024-08-02
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

not applicable (submitted trial is a comparative bioavailability study)

VersionLevelCodeTermSystem organ class
20.0 PT 10031282 Osteoporosis 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Oractive Swiss AG

Sponsor organisation
Oractive Swiss AG
Address
Industriestrasse 47
City
Zug
Postcode
6300
Country
Switzerland

Scientific contact point

Organisation
Oractive Swiss AG
Contact name
Timo Schmidt

Public contact point

Organisation
Oractive Swiss AG
Contact name
Georg Tölkhaus

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 24 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Quinta-Analytica s.r.o.
management, Prazska 1486/18c, Hostivar, Prague

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2024-09-12 2024-10-02 2024-09-12 2024-09-24

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-03 Czechia Acceptable
2024-08-02
2024-08-02